MitoRx Therapeutics' CEO shares insights on fundraising and pitching to investors
UK Innovation & Science Seed Fund - 20-Jul-2022Effectively communicating to investors will translate an ideology into a social benefit
Join the club for FREE to access the whole archive and other member benefits.
CEO and co-founder at MitoRx Therapeutics
Jon Rees is the CEO and co-founder at MitoRx Therapeutics. He has 16 years of working experience in industry including business development for Takeda Pharma Rare Diseases, VC deal sourcing for LSP.vc, successfully advising Ducentis BioTherapeutics on fundraising. Tranformative decade as spin-out CEO of leading biotech network OBN/BioTrinity. PKD patient charity trustee.
Jon completed his post-doc at the University of Oxford, PhD from the Royal Holloway University of London, a Masters with Distinction from LJMU and a BSc from University of Manchester Institute for Science and Technology.
Visit website: https://www.mitorxtherapeutics.com/#Our-team#JonRees
See also: MitoRx Therapeutics - Pre-clinical stage rare disease biotech company aiming to develop treatments for degenerative diseases
Details last updated 26-Apr-2022
Pre-clinical stage rare disease biotech company aiming to develop treatments for degenerative diseases
Effectively communicating to investors will translate an ideology into a social benefit
Targeting age-related diseases, the company's pre-clinical compounds to progress to the clinic